Thomas J. Semrad

1.4k total citations
51 papers, 890 citations indexed

About

Thomas J. Semrad is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Thomas J. Semrad has authored 51 papers receiving a total of 890 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Thomas J. Semrad's work include Colorectal Cancer Treatments and Studies (13 papers), Lung Cancer Treatments and Mutations (10 papers) and Cancer Genomics and Diagnostics (6 papers). Thomas J. Semrad is often cited by papers focused on Colorectal Cancer Treatments and Studies (13 papers), Lung Cancer Treatments and Mutations (10 papers) and Cancer Genomics and Diagnostics (6 papers). Thomas J. Semrad collaborates with scholars based in United States, Canada and United Kingdom. Thomas J. Semrad's co-authors include Philip C. Mack, Robert T. OʼDonnell, Danielle Harvey, Hong Zhou, Richard H. White, Helen K. Chew, Ted Wun, David R. Gandara, Primo N. Lara and Karen Kelly and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

Thomas J. Semrad

50 papers receiving 878 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas J. Semrad United States 15 395 257 237 162 135 51 890
Tracy Proverbs‐Singh United States 7 688 1.7× 210 0.8× 268 1.1× 75 0.5× 126 0.9× 14 1.1k
Matteo Brighenti Italy 12 628 1.6× 182 0.7× 316 1.3× 63 0.4× 66 0.5× 38 869
Anastasios Dimou United States 16 481 1.2× 201 0.8× 311 1.3× 115 0.7× 57 0.4× 67 800
Nicola Steele United Kingdom 18 677 1.7× 722 2.8× 344 1.5× 156 1.0× 54 0.4× 41 1.4k
Lothar Müller Germany 13 424 1.1× 163 0.6× 269 1.1× 131 0.8× 197 1.5× 71 850
Hazem El‐Osta United States 16 434 1.1× 262 1.0× 234 1.0× 109 0.7× 22 0.2× 35 893
Claudia Proto Italy 18 780 2.0× 213 0.8× 531 2.2× 150 0.9× 36 0.3× 93 1.2k
Bart C. Kuenen Netherlands 17 519 1.3× 511 2.0× 264 1.1× 176 1.1× 132 1.0× 31 1.2k
Roberta Camisa Italy 17 872 2.2× 448 1.7× 289 1.2× 290 1.8× 27 0.2× 44 1.5k
Pınar Saip Türkiye 21 606 1.5× 288 1.1× 520 2.2× 354 2.2× 29 0.2× 115 1.6k

Countries citing papers authored by Thomas J. Semrad

Since Specialization
Citations

This map shows the geographic impact of Thomas J. Semrad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas J. Semrad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas J. Semrad more than expected).

Fields of papers citing papers by Thomas J. Semrad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas J. Semrad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas J. Semrad. The network helps show where Thomas J. Semrad may publish in the future.

Co-authorship network of co-authors of Thomas J. Semrad

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas J. Semrad. A scholar is included among the top collaborators of Thomas J. Semrad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas J. Semrad. Thomas J. Semrad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sukrithan, Vineeth, Briant Fruth, Rui Qin, et al.. (2023). A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors. Endocrine Related Cancer. 30(11). 4 indexed citations
2.
Chen, Justin A., Jasmine C. Huynh, Chun-Yi Wu, et al.. (2022). A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer. Cancer Chemotherapy and Pharmacology. 90(3). 217–228. 5 indexed citations
3.
Semrad, Thomas J., Qian Li, Melanie Goldfarb, et al.. (2021). Influence of Socioeconomic Status on Incident Medical Conditions in Two-Year Survivors of Adolescent or Young Adult Differentiated Thyroid Cancer. Journal of Adolescent and Young Adult Oncology. 10(5). 521–533. 8 indexed citations
4.
Semrad, Thomas J., Edward Kim, Tianhong Li, et al.. (2021). Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 88(2). 335–341. 10 indexed citations
5.
Zimmermann, Maike, Tao Li, Thomas J. Semrad, et al.. (2020). Oxaliplatin–DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy. Molecular Cancer Therapeutics. 19(4). 1070–1079. 20 indexed citations
6.
Lin, Patrick S. & Thomas J. Semrad. (2018). Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview. Methods in molecular biology. 1765. 281–297. 10 indexed citations
7.
Liu, Stephen V., Susan Groshen, Karen Kelly, et al.. (2018). A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 82(4). 723–732. 5 indexed citations
8.
9.
El-Khoueiry, Anthony B., Robert T. OʼDonnell, Thomas J. Semrad, et al.. (2018). A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology. 81(5). 957–963. 14 indexed citations
10.
11.
Semrad, Thomas J., Edward Kim, Michael Tanaka, et al.. (2016). Phase II study of dovitinib in patients progressing on anti-vascular endothelial growth factor therapy. Cancer Treatment and Research Communications. 10. 21–26. 25 indexed citations
12.
13.
Tomlinson, Benjamin, James A. Thomson, John S. Bomalaski, et al.. (2015). Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors. Clinical Cancer Research. 21(11). 2480–2486. 66 indexed citations
14.
Semrad, Thomas J., et al.. (2015). Integrating Chemotherapy into the Management of Oligometastatic Colorectal Cancer: Evidence-Based Approach Using Clinical Trial Findings. Annals of Surgical Oncology. 22(S3). 855–862. 7 indexed citations
15.
Semrad, Thomas J., et al.. (2015). Initial Treatment Patterns in Younger Adult Patients with Differentiated Thyroid Cancer in California. Thyroid. 25(5). 509–513. 15 indexed citations
16.
Gill, Amandeep, et al.. (2015). Implications of lymph node retrieval in locoregional rectal cancer treated with chemoradiotherapy: A California Cancer Registry Study. European Journal of Surgical Oncology. 41(5). 647–652. 13 indexed citations
17.
Lara, Primo N., James Moon, Mary W. Redman, et al.. (2015). Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clinical Lung Cancer. 17(2). 113–118.e2. 11 indexed citations
18.
Semrad, Thomas J., et al.. (2013). Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors. Anti-Cancer Drugs. 24(6). 636–640. 12 indexed citations
19.
Semrad, Thomas J. & Philip C. Mack. (2011). Fibroblast Growth Factor Signaling in Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 13(2). 90–95. 35 indexed citations
20.
Semrad, Thomas J., et al.. (2001). Mutational Analysis of Immunoglobulin Germline Derived Vλ4A Light Chains in Rheumatoid Arthritis. Clinical Immunology. 99(2). 276–282. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tracy Proverbs‐Singh Breakdown of academic impact, for papers by Matteo Brighenti Breakdown of academic impact, for papers by Anastasios Dimou Breakdown of academic impact, for papers by Nicola Steele Breakdown of academic impact, for papers by Lothar Müller Breakdown of academic impact, for papers by Hazem El‐Osta Breakdown of academic impact, for papers by Claudia Proto Breakdown of academic impact, for papers by Bart C. Kuenen Breakdown of academic impact, for papers by Roberta Camisa Breakdown of academic impact, for papers by Pınar Saip
Rankless by CCL
2026